Citations

Mayo Clinic

Showing 10 of 108599 citations.

Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial
Miller, Dylan V. , Jenkins, Robert B. , Lingle, Wilma L., Davidson, Nancy E. , Martino, Silvana, Dakhil, Shaker R. , Perez, Edith A. , Kaufman, Peter A.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 568-568

10.1200/jco.2004.22.90140.568 Get It

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial
Perez, Edith A. , Davidson, Nancy E. , Martino, Silvana, Lingle, Wilma L., Flynn, Patrick J. , Visscher, Daniel W., Jenkins, Robert B. , Suman, Vera J. , Kaufman, Peter A. , Ingle, James N.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 567-567

10.1200/jco.2004.22.90140.567 Get It

N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study
Goldberg, Richard M. , Morton, Roscoe F., Fuchs, Charles S. , Ramanathan, R. K., Findlay, B., Pitot, H., Sargent, Daniel J. , Williamson, Stephen K. , Alberts, Steven R.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3621-3621

10.1200/jco.2004.22.90140.3621 Get It

SWOG 99–16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA)
Petrylak, D. P., Tangen, C., Lara, P. N. , Jones, J., Talpin, M. E., Burch, P., Greene, G., Crawford, E. D., Hussain, Maha , Burch, P. A., Small, Eric J.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3-3

10.1200/jco.2004.22.90140.3 Get It

Intervention radiology for venous thrombosis: early thrombus removal using invasive methods
Casanegra, Ana I. , McBane, Robert D. , Bjarnason, Haraldur , McBane, Robert , Casanegra, Ana I , Bjarnason, Haraldur

British Journal of Haematology | April 5, 2017 | Volume: 177 | Issue: 2 | Pages: 173-184

10.1111/bjh.14581 | PMID 28369771 Get It

SummaryThe post thrombotic syndrome is one of the most dreaded complications of proximal deep vein thrombosis. This syndrome leads to pain and suffering with leg swelling, recalcitrant ulceration and venous claudication which greatly impairs mobility and quality of life. The prevalence can be high in patients with iliofemoral venous involvement particularly in the setting of a proximal venous stenosis, such as occurs in May Thurner syndrome. Anticoagulation alone does not reduce the likelihood of this outcome. Compression therapy may be effective but garment discomfort limits its implementation. Pharmacomechanical thrombectomy, which combines catheter‐directed thrombolysis with mechanical thrombus dissolution, provides an attractive treatment strategy for such patients. The rationale and delivery of pharmacomechanical thrombectomy, including patient selection and adjunctive antithrombotic therapy, will be reviewed in addition to tips and tricks for managing difficult patient scenarios.
A pooled analysis of demographic characteristics and clinical outcomes of phase I oncology clinical trials, the Mayo Clinic experience
Atherton, Pamela J. , Jasperson, Britta, Sloan, Jeffrey A., Mandrekar, Sumithra J. , Smith, Denise J., Erlichman, Charles , Adjei, Alex A.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 9724-9724

10.1200/jco.2004.22.90140.9724 Get It

KS1 (KRAB suppressor of transformation 1) and BMP3b (bone morphogenetic protein 3b) gene promoter hypermethylation is a common epigenetic event in breast cancer
Molina, Julian R. , Alzein, N. J., Lingle, Wilma L., Fernandez-Zampico, M., Hartmann, Lynn C. , Urrutia, Raúl

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 9608-9608

10.1200/jco.2004.22.90140.9608 Get It

Pap test and a new biomarker-based technology for enhancing the visibility of abnormal cells
Sundeen, Joseph E., Smith, Wendy M. , Marković, Nataša , Marković, Olivera , Markovic, Svetomir N.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 9561-9561

10.1200/jco.2004.22.90140.9561 Get It

Methylation of the mitotic checkpoint genes BUB3 and BUBR1 in lung cancer
Alzein, N. J., Deursen, Jan van, Molina, Julian R.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 9558-9558

10.1200/jco.2004.22.90140.9558 Get It

Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience
Breitfeld, P P, Anderson, J R , Rodeberg, David A. , Qualman, S., Wolden, S., Meyer, William H. , Kao, Simon C.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 8513-8513

10.1200/jco.2004.22.90140.8513 Get It